Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fractyl HealthGUTS +1.15%11 Return-on-Tangible-Equity is 239.16% as of Mar. 2026. GuruFocus rates GUTS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,201 Biotechnology companies, Fractyl Health ranks worse than 98.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fractyl Health's annualized net income for the quarter that ended in Mar. 2026 was $36.87 Mil. Fractyl Health's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $15.42 Mil. Therefore, Fractyl Health's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 239.16%.
The historical rank and industry rank for Fractyl Health's Return-on-Tangible-Equity or its related term are showing as below:
GUTS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3413.43 Med: -744.17 Max: -744.17
Current: -3413.43
During the past 7 years, Fractyl Health's highest Return-on-Tangible-Equity was -744.17%. The lowest was -3,413.43%. And the median was -744.17%.
GUTS's Return-on-Tangible-Equity is ranked worse than 98.92% of 1201
companies
in the Biotechnology industry
Industry Median: -42.68
vs GUTS: -3413.43
Fractyl Health (NAS:GUTS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Fractyl Health Return-on-Tangible-Equity Related Terms
Fractyl Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Fractyl Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GUTS vs ENGN, ANIX, VTVT: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Fractyl Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fractyl Health Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fractyl Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Fractyl Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 239.16% mean?
Fractyl Health (GUTS) has a Return-on-Tangible-Equity of 239.16% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fractyl Health and its competitors. According to the industry distribution chart, Fractyl Health ranks #1188 out of 1201 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Fractyl Health's Return-on-Tangible-Equity too high?
Fractyl Health's current Return-on-Tangible-Equity is 239.16%. Based on the distribution chart, Fractyl Health ranks #1188 out of 1201 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fractyl Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's Return-on-Tangible-Equity compare to ENGN and ANIX?
According to the Biotechnology industry distribution chart, Fractyl Health ranks #1188 out of 1201 companies for Return-on-Tangible-Equity. This places Fractyl Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fractyl Health and its competitors. Fractyl Health's current Return-on-Tangible-Equity is 239.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current Return-on-Tangible-Equity of 239.16%. The current Return-on-Tangible-Equity is 239.16%. Fractyl Health's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Fractyl Health (GUTS), the current Return-on-Tangible-Equity is 239.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
11GF Score
Get the complete analysis for GUTS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GUTS has been successfully added to your 
